Cel-Sci (CVM) Stock Price, News & Analysis

Company Overview

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells. Multikine has been evaluated in a pivotal Phase III clinical trial, and CEL-SCI has conducted additional clinical studies and manufacturing development to support potential registration in the United States and abroad. Beyond Multikine, the company is advancing early-stage programs in infectious disease and oncology that leverage its expertise in immune modulation.

CEL-SCI has carried out clinical trials and manufacturing activities in multiple regions, including North America, Europe, Latin America and South Africa. Its research and development operations encompass in-house laboratories in Virginia and collaborations with contract research organizations around the world. This global footprint reflects the company’s commitment to rigorous clinical testing and regulatory engagement in key markets.

Under the leadership of President and Chief Executive Officer Geert Kersten, CEL-SCI maintains a small executive team supported by a board of directors with expertise in biotechnology, clinical operations and regulatory affairs. The company’s scientific staff comprises immunologists, process development specialists and clinical trial managers who collectively steer CEL-SCI’s programs from preclinical research through late-stage development.

Key Stats

• Today's Range: $1.47 to $1.57
• 50-Day Range: $1.19 to $4.95
• 52-Week Range: $0.89 to $13.48
• Volume: 185,089 shs
• Average Volume: 227,107 shs
• Market Capitalization: $12.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cel-Sci Stock Analysis - MarketRank™

Cel-Sci scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cel-Sci.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cel-Sci is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cel-Sci is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cel-Sci has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.71% of the float of Cel-Sci has been sold short.

Short Interest Ratio / Days to Cover

Cel-Sci has a short interest ratio ("days to cover") of 8.11.

Change versus previous month

Short interest in Cel-Sci has recently increased by 50.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cel-Sci does not currently pay a dividend.

Dividend Growth

Cel-Sci does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.34

News Sentiment

Cel-Sci has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cel-Sci this week, compared to 0 articles on an average week.

Search Interest

8 people have searched for CVM on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cel-Sci to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cel-Sci insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.93% of the stock of Cel-Sci is held by insiders.

Percentage Held by Institutions

12.08% of the stock of Cel-Sci is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 5/21/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:CVM
• CIK: 725363
• Web: cel-sci.com
• Phone: 703-506-9460
• Fax: 703-506-9471
• Employees: 43
• Year Founded: 1983

Profitability

• EPS (Trailing Twelve Months): ($9.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -274.86%
• Return on Assets: -126.47%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 0.60
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.81 per share
• Price / Book: 1.82

Miscellaneous

• Outstanding Shares: 8,490,000
• Free Float: 7,650,000
• Market Cap: $12.52 million
• Optionable: Optionable
• Beta: 0.70